CN102416181B - 生物降解高分子键合光活性Pt(IV)抗癌药胶束及制备方法 - Google Patents
生物降解高分子键合光活性Pt(IV)抗癌药胶束及制备方法 Download PDFInfo
- Publication number
- CN102416181B CN102416181B CN 201110416179 CN201110416179A CN102416181B CN 102416181 B CN102416181 B CN 102416181B CN 201110416179 CN201110416179 CN 201110416179 CN 201110416179 A CN201110416179 A CN 201110416179A CN 102416181 B CN102416181 B CN 102416181B
- Authority
- CN
- China
- Prior art keywords
- photolytic activity
- platinum
- high molecular
- biodegradable high
- cancer drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 83
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 239000000693 micelle Substances 0.000 title claims abstract description 73
- 229920000642 polymer Polymers 0.000 title claims abstract description 56
- 230000001093 anti-cancer Effects 0.000 title abstract description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 563
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 83
- -1 polyethylene Polymers 0.000 claims abstract description 36
- 239000004698 Polyethylene Substances 0.000 claims abstract description 26
- 229920000573 polyethylene Polymers 0.000 claims abstract description 26
- 229920000656 polylysine Polymers 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 229920000428 triblock copolymer Polymers 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 188
- 230000000694 effects Effects 0.000 claims description 167
- 239000002246 antineoplastic agent Substances 0.000 claims description 108
- 229940041181 antineoplastic drug Drugs 0.000 claims description 105
- 239000000243 solution Substances 0.000 claims description 67
- 150000001875 compounds Chemical class 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 65
- 238000006243 chemical reaction Methods 0.000 claims description 64
- 239000011259 mixed solution Substances 0.000 claims description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- 238000003756 stirring Methods 0.000 claims description 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 40
- 239000007864 aqueous solution Substances 0.000 claims description 37
- 238000004108 freeze drying Methods 0.000 claims description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 34
- 239000008176 lyophilized powder Substances 0.000 claims description 32
- 150000008064 anhydrides Chemical class 0.000 claims description 30
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical compound [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 claims description 29
- 238000000502 dialysis Methods 0.000 claims description 27
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- FPJNQJHCHVUNTK-UHFFFAOYSA-N platinum;dihydrate Chemical compound O.O.[Pt] FPJNQJHCHVUNTK-UHFFFAOYSA-N 0.000 claims description 24
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 229920001610 polycaprolactone Polymers 0.000 claims description 18
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 17
- 229940095758 cantharidin Drugs 0.000 claims description 17
- 229930008397 cantharidin Natural products 0.000 claims description 17
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 claims description 15
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 15
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 15
- 229940014800 succinic anhydride Drugs 0.000 claims description 15
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 14
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 14
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 14
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 12
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 claims description 12
- 230000001376 precipitating effect Effects 0.000 claims description 12
- 229920001400 block copolymer Polymers 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 10
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 claims description 8
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 108010039918 Polylysine Proteins 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 8
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 claims description 8
- 229920000728 polyester Polymers 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 7
- 125000005587 carbonate group Chemical group 0.000 claims description 6
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical compound CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 5
- 150000004945 aromatic hydrocarbons Chemical group 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 150000001924 cycloalkanes Chemical class 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 4
- GTZADBLTXYJPQL-UHFFFAOYSA-N [N+](=O)([O-])[O-].O.[Pt+2].[N+](=O)([O-])[O-] Chemical compound [N+](=O)([O-])[O-].O.[Pt+2].[N+](=O)([O-])[O-] GTZADBLTXYJPQL-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229910000474 mercury oxide Inorganic materials 0.000 claims description 4
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229920005604 random copolymer Polymers 0.000 claims description 4
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 4
- IGWMPTNCTVHTOF-UHFFFAOYSA-M [Pt]O Chemical class [Pt]O IGWMPTNCTVHTOF-UHFFFAOYSA-M 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 150000003057 platinum Chemical class 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 239000013557 residual solvent Substances 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 229960001756 oxaliplatin Drugs 0.000 abstract description 2
- 230000003287 optical effect Effects 0.000 abstract 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 229920000359 diblock copolymer Polymers 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 311
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- 229960004316 cisplatin Drugs 0.000 description 16
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 13
- 108010060427 methoxy poly(ethylene glycol)-b-poly(epsilon-caprolactone)-b-poly(L-lysine) Proteins 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 238000005286 illumination Methods 0.000 description 10
- 229920002521 macromolecule Polymers 0.000 description 8
- 239000000178 monomer Substances 0.000 description 7
- 150000005676 cyclic carbonates Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000009415 formwork Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 0 CC(C)C([C@]1C(CCC*[C@]2IN(*)C2)C(C)C1[C+])I(C)* Chemical compound CC(C)C([C@]1C(CCC*[C@]2IN(*)C2)C(C)C1[C+])I(C)* 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 102100028735 Dachshund homolog 1 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000915055 Homo sapiens Dachshund homolog 1 Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012930 cell culture fluid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000002121 endocytic effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940059574 pentaerithrityl Drugs 0.000 description 3
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 229920013747 hydroxypolyethylene Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 238000007540 photo-reduction reaction Methods 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- KGVREUSVIJADPE-UHFFFAOYSA-N platinum(4+) tetraazide Chemical class [N-]=[N+]=N[Pt](N=[N+]=[N-])(N=[N+]=[N-])N=[N+]=[N-] KGVREUSVIJADPE-UHFFFAOYSA-N 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001420 poly(caprolactone-co-lactic acid) Polymers 0.000 description 1
- 108700040839 poly(ethylene glycol)-b-poly(lactide)-b-poly(glutamic acid) Proteins 0.000 description 1
- 229920001553 poly(ethylene glycol)-block-polylactide methyl ether Polymers 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- CZMAXQOXGAWNDO-UHFFFAOYSA-N propane-1,1,2-triol Chemical compound CC(O)C(O)O CZMAXQOXGAWNDO-UHFFFAOYSA-N 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical class O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QXJQHYBHAIHNGG-UHFFFAOYSA-N trimethylolethane Chemical compound OCC(C)(CO)CO QXJQHYBHAIHNGG-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
药物 | 顺铂 | Pt(IV)-(OH)(COOH) | 高分子-Pt(IV)键合药 |
培养2小时 | 34 | 17 | 252 |
培养6小时 | 112 | 34 | 1140 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110416179 CN102416181B (zh) | 2011-12-14 | 2011-12-14 | 生物降解高分子键合光活性Pt(IV)抗癌药胶束及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110416179 CN102416181B (zh) | 2011-12-14 | 2011-12-14 | 生物降解高分子键合光活性Pt(IV)抗癌药胶束及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102416181A CN102416181A (zh) | 2012-04-18 |
CN102416181B true CN102416181B (zh) | 2013-07-24 |
Family
ID=45940979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110416179 Expired - Fee Related CN102416181B (zh) | 2011-12-14 | 2011-12-14 | 生物降解高分子键合光活性Pt(IV)抗癌药胶束及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102416181B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588818B (zh) * | 2013-11-26 | 2016-06-01 | 中国科学院长春应用化学研究所 | 一种具有抗癌活性的化合物及其制备方法 |
CN105254836B (zh) * | 2015-10-21 | 2017-12-26 | 中国科学院长春应用化学研究所 | 主链含光敏前药两亲性高分子、制备方法及其纳米胶束 |
CN105254867B (zh) * | 2015-10-21 | 2017-11-17 | 中国科学院长春应用化学研究所 | 主链含双抗癌药两亲性高分子、制备方法及其纳米胶束 |
CN105622674B (zh) * | 2016-02-29 | 2018-02-02 | 东南大学 | 一类含有生物活性基团的四价铂配合物及其制备方法 |
CN108210455A (zh) * | 2016-12-19 | 2018-06-29 | 湖南尔康湘药制药有限公司 | 一种碳酸锌纳米胶束制剂及制备方法 |
CN107445997B (zh) * | 2017-07-03 | 2020-11-24 | 上海交通大学 | 一种光化疗铂类前药及其制备方法、应用 |
CN108144067B (zh) | 2017-12-27 | 2020-11-24 | 安徽大学 | 四价铂化合物-双环双键两亲性聚合物前药、其纳米胶束及制备方法和应用 |
CN109745338B (zh) * | 2019-01-17 | 2021-03-30 | 南开大学 | 包载伏立诺他具有还原响应的Pt(IV)聚合物前药胶束的制备方法及应用 |
CN110755639A (zh) * | 2019-11-13 | 2020-02-07 | 浙江大学 | 聚乙二醇-树枝状聚赖氨酸/酸酐-顺铂复合物及其制备方法和应用 |
CN110950915B (zh) * | 2019-12-24 | 2022-07-22 | 玉林师范学院 | 一种新型大黄酸类-铂(iv)前体抗癌配合物及其合成方法与应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102120036B (zh) * | 2011-02-22 | 2013-07-24 | 中国科学院长春应用化学研究所 | 生物降解的高分子键合Pt(IV)类抗癌药物纳米胶束及其制备方法 |
-
2011
- 2011-12-14 CN CN 201110416179 patent/CN102416181B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102416181A (zh) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102416181B (zh) | 生物降解高分子键合光活性Pt(IV)抗癌药胶束及制备方法 | |
CN102120036B (zh) | 生物降解的高分子键合Pt(IV)类抗癌药物纳米胶束及其制备方法 | |
Xiao et al. | Recent progress in polymer-based platinum drug delivery systems | |
Gothwal et al. | Polymeric micelles: recent advancements in the delivery of anticancer drugs | |
Zhang et al. | Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers | |
Delplace et al. | Recent trends in the design of anticancer polymer prodrug nanocarriers | |
Callari et al. | Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment | |
Najjar et al. | Recent approaches to platinum (IV) prodrugs: a variety of strategies for enhanced delivery and efficacy | |
CN101679021B (zh) | 药物颗粒送递 | |
CN103172819B (zh) | 侧链带有氨基的可生物降解聚氨酯及其制备方法和用途 | |
Tawfik et al. | Naturally modified nonionic alginate functionalized upconversion nanoparticles for the highly efficient targeted pH-responsive drug delivery and enhancement of NIR-imaging | |
JP2016523915A (ja) | ドセタキセルポリマーナノ粒子及びそれを使用する癌の治療方法 | |
Du et al. | Nanoparticle delivery of photosensitive Pt (IV) drugs for circumventing cisplatin cellular pathway and on-demand drug release | |
Song et al. | A cross-linked polymeric micellar delivery system for cisplatin (IV) complex | |
He et al. | Photoresponsive metallopolymer nanoparticles for cancer theranostics | |
CN105384920B (zh) | 一类含硒或碲的聚合物及其制备方法与应用 | |
Xiao et al. | A complex of cyclohexane-1, 2-diaminoplatinum with an amphiphilic biodegradable polymer with pendant carboxyl groups | |
CN113952463B (zh) | 一种纳米诊疗剂及其制备方法与应用 | |
AU2016326747A1 (en) | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate | |
Cao et al. | Porphine functionalized nanoparticles of star-shaped poly (ε-caprolactone)-bD-α-tocopheryl polyethylene glycol 1000 succinate biodegradable copolymer for chemophotodynamic therapy on cervical cancer | |
CN102600063A (zh) | 一种高载药量姜黄素胶束的制备方法 | |
JPH03504859A (ja) | 白金―ポリマー錯塩および抗腫瘍剤としてのそれらの用途 | |
CN103720675A (zh) | 一种具有氧化还原敏感的姜黄素前药胶束、胶束单体及其制备方法 | |
António et al. | Polymeric encapsulation of a ruthenium (ii) polypyridyl complex: from synthesis to in vivo studies against high-grade epithelial ovarian cancer | |
CN112480289B (zh) | 一种共担载阿霉素和铂类药物的核壳结构型壳聚糖基纳米前药及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181024 Address after: No. 9, river Hai Dong Road, Changzhou, Jiangsu Province Patentee after: CHANGZHOU INSTITUTE OF ENERGY STORAGE MATERIALS & DEVICES Address before: 130022 5625 people's street, Chaoyang District, Changchun, Jilin. Patentee before: CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190412 Address after: 130015 No. 5218 Longhu Road, High-tech North District, Changchun City, Jilin Province Patentee after: Changchun applied chemical science and Technology General Corporation of Chinese Academy of Sciences Address before: No. 9, river Hai Dong Road, Changzhou, Jiangsu Province Patentee before: Changzhou Institute of Energy Storage Materials & Devices |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190628 Address after: 132000 Jilin Province Longtan District Tiedong District Longdong District 5 Units 91 Patentee after: Jilin Xinhua Investment Co.,Ltd. Address before: 130015 No. 5218 Longhu Road, High-tech North District, Changchun City, Jilin Province Patentee before: Changchun applied chemical science and Technology General Corporation of Chinese Academy of Sciences |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190724 Address after: 130012 No. 329 Xi'an Road, Chuanying District, Jilin Province Patentee after: Jilin Boyuxiangshi Industry and Trade Co.,Ltd. Address before: 132000 Jilin Province Longtan District Tiedong District Longdong District 5 Units 91 Patentee before: Jilin Xinhua Investment Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130724 |